MGC Pharmaceuticals’ Roby Zomer on positive COVID-19 trial results

MGC Pharmaceuticals’ chief executive Roby Zomer joined Proactive to talk about interim results from a small-scale patient trial of its CimetrA treatment.

The CimetrA trail is in regards to COVID-19, but the treatment may have many other applications in aiding autoimmune response, and, has shown no complications in those to whom it was administered, MGC note.

An expanded trial is in the offing and with the latest news, shares jumped 8% in Wednesday’s early deals.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews